Rebecca Porter, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the emerging significance of folate receptor alpha (FRa) expression in endometrial cancer, especially in light of promising role of mirvetuximab soravtansine with pembrolizumab in treating endometrial cancer. FRa expression might help clinicians in evaluating which patients will benefit from the aforementioned therapy, as well as sequence available antibody-drug conjugates and elucidate mechanisms of cross resistance. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.